biotech

10+ articles

2025 Predictions AI AI Chips AI Development AI Innovations

AI Takes Center Stage: Google Unleashes Gemma 4, OpenAI Buys Talk Show, and Anthropic Dives into Biotech!

Get ready for a whirlwind of AI innovations as Google, OpenAI, and Anthropic drive the future of artificial intelligence. Google's Gemma 4 hits the market as a game-changing open-source AI model perfect for developers and hobbyists. OpenAI, not to be outdone, acquires a popular media talk show to boost the public perception of AI and its CEO, Sam Altman. Not stopping there, Anthropic is investing in biotech startups to combine AI's power with medicine, potentially creating groundbreaking treatments. This collision of technology, media, and biotech opens the door for new possibilities.

Apr 5

AI Takes Center Stage: Google Unleashes Gemma 4, OpenAI Buys Talk Show, and Anthropic Dives into Biotech!

Top Startups That Stole the Show at Y Combinator's W26 Demo Day!

TechCrunch highlights 16 standout startups from the W26 Demo Day, showcasing diverse innovations from AI to climate tech, proving once again why Y Combinator is the breeding ground for the next big things. Discover the ingenious minds ready to reshape our future!

Mar 30

Top Startups That Stole the Show at Y Combinator's W26 Demo Day!

Templum and SoFi Team Up to Bring Private Market Gems to Members!

Templum is partnering with SoFi to offer its members a unique opportunity to invest in Perplexity AI, OpenAI, and Colossal Biosciences through the Cosmos Fund. Running from March 5 to 30, 2026, this exclusive chance is open to qualified investors and represents a push to democratize access to high-demand private market investments. From conversational AI to mind-blowing biotech projects, these companies are sure to draw investor excitement—so get ready!

Mar 6

Templum and SoFi Team Up to Bring Private Market Gems to Members!

Chan Zuckerberg Initiative Shifts to AI in Biomedical Research, Announces Layoffs

The Chan Zuckerberg Initiative (CZI) has revealed layoffs affecting 8% of its workforce in a strategic pivot towards AI-driven biomedical research. This move represents a significant shift from previous education and social justice efforts to focus on advancing health science through AI innovation. CZI's flagship Biohub network will be the focal point of this transition, aiming to 'cure or prevent all diseases.'

Feb 1

Chan Zuckerberg Initiative Shifts to AI in Biomedical Research, Announces Layoffs

AI Research Skyrockets in 2025, But R&D Hiring Lags Behind

The U.S. R&D job market in 2025 presents a puzzling scenario: AI research is booming with groundbreaking innovations, while actual hiring in R&D roles remains stagnant. Federal funding cuts, tech layoffs, and an oversupply of skilled workers are contributing to this paradox, creating fierce competition for stable traditional lab roles.

Dec 4

AI Research Skyrockets in 2025, But R&D Hiring Lags Behind

Stock Movers: Tech Giants and Biotech Firms Make Big Waves!

Explore the latest trends in the stock market as NVIDIA surges on AI chip demand, while Tesla falters with revised production guidance. Learn why biotech stocks are buzzing with the FDA's new drug approval, and see what's driving the retail sector's holiday gains.

Dec 1

Stock Movers: Tech Giants and Biotech Firms Make Big Waves!

Elon Musk Brings Neuralink and xAI Back to the Bay Area: Tech Revival?

Elon Musk is reversing course by expanding his company Neuralink, along with xAI, into the Bay Area, leasing a huge office space in South San Francisco. This move could reignite the biotech and tech sectors in the region, despite Musk's previous plans to relocate to Texas. With a strong focus on brain-computer interfaces and AI development, Musk's expansion brings new life to Northern California’s innovation landscape.

Oct 11

Elon Musk Brings Neuralink and xAI Back to the Bay Area: Tech Revival?

Biotech Firm's AI Lung Disease Breakthrough Amid Hong Kong IPO

A biotech company has announced a major AI-driven breakthrough in discovering new drugs for lung disease, coinciding with its third attempt at a Hong Kong IPO.

Jun 5

Biotech Firm's AI Lung Disease Breakthrough Amid Hong Kong IPO

Mural Oncology Hits a Wall: IL-2 Therapy Flop Triggers Major Layoffs

Mural Oncology has announced a drastic 90% reduction in its workforce and has halted the development of its IL-2 variant, nemvaleukin alfa, following disappointing clinical trial results in ovarian cancer and melanoma. As the company seeks strategic alternatives—including a potential sale or merger—investors saw a surprising rise in stock prices, indicating confidence in Mural's remaining assets and cash reserves. This setback echoes broader challenges within the IL-2 therapy field but leaves room for future exploration.

Apr 16

Mural Oncology Hits a Wall: IL-2 Therapy Flop Triggers Major Layoffs

Nerdio Leads the Week with Megadeal Amid Biotech Surge and Funding Slowdown

In a week marked by a slowdown in massive funding rounds, Nerdio takes center stage with a whopping $500 million equity raise, landing a $1.2 billion valuation. As venture capital cautiousness prevails, biotech giants like Latigo Biotherapeutics and Curevo also make waves, reflecting strong investor confidence in the industry.

Mar 22

Nerdio Leads the Week with Megadeal Amid Biotech Surge and Funding Slowdown